Denna sida på svenska

Leszek Stawiarz

Project coordinator

Visiting address : Widerströmska Huset Tomtebodavägen 18a, 5 Tr 171 77 Stockholm, Sweden
Postal address : Department of Clinical Neuroscience (CNS), K8, Neuro Hillert, Widerströmska Huset Tomtebodavägen 18a, 5 Tr 171 77 Stockholm, Sweden

Academic honors, awards and prizes

Honorary Member of Swedish MS Society, 2008.

Publications

Importance of early treatment initiation in the clinical course of multiple sclerosis
Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedström Ak, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2017;23(9):1233-1240

Re: Declines in the diagnosis of primary progressive MS-A critical change in phenotype or critical measurement error?
Westerlind H, Stawiarz L, Fink K, Hillert J, Manouchehrinia A
Multiple sclerosis (Houndmills, Basingstoke, England) 2017;23(2):305-307

Adaptation and preliminary testing of Six Neuro-QoL Item banks for use in the Swedish neuro-registries/multiple sclerosis registry (NEUROreg/MSreg)
Chaplin Je, Lycke K, Egertz L, Helmersson E, Stawiarz L, Hillert J
MULTIPLE SCLEROSIS JOURNAL 2016;:385-386

Adapting neuro-QoL to the Swedish neuroregistries/multiple sclerosis registry
Chaplin Je, Lycke K, Egertz L, Helmersson E, Stawiarz L, Hillert J
QUALITY OF LIFE RESEARCH 2016;:147-147

A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study
Westerlind H, Stawiarz L, Fink K, Hillert J, Manouchehrinia A
Multiple sclerosis (Houndmills, Basingstoke, England) 2016;22(8):1071-9

Importance of early treatment initiation in the clinical course of multiple sclerosis
Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedstrom Ak, et al
MULTIPLE SCLEROSIS JOURNAL 2016;:642-642

National, real-time monitoring of MS-immunotherapy patterns with visualisation and analysis platform (VAP) implemented in swedish MS-registry
Stawiarz L, Hagel E, Eriksson H, Hillert J
MULTIPLE SCLEROSIS JOURNAL 2016;:648-648

A significant decrease in the diagnosis of primary progressive multiple sclerosis: a cohort study
Westerlind H, Stawiarz L, Fink K, Hillert J, Manouchehrinia A
MULTIPLE SCLEROSIS JOURNAL 2015;:56-56

"Function Watch" - a real time, graphical composite representation of MS patients' health status as a decision support tool in daily clinical practice
Stawiarz L, Hagel E, Eriksson H, Hillert J
MULTIPLE SCLEROSIS JOURNAL 2015;:417-417

The influence of immunomodulatory treatment on the clinical course of multiple sclerosis
Kavaliunas A, Stawiarz L, Hedbom J, Glaser A, Hillert J
Advances in experimental medicine and biology 2015;822():19-24

The Swedish MS registry – clinical support tool and scientific resource
Hillert J, Stawiarz L
Acta neurologica Scandinavica 2015;132(199):11-9

Age-specific sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg)
Boström I, Stawiarz L, Landtblom Am
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(4):513-4

A visualization and analysis platform in the Swedish national MS registry for real-time data feedback
Swedish Ms Registry, Stawiarz L, Hagel E, Eriksson H, Hillert J
MULTIPLE SCLEROSIS JOURNAL 2014;:163-164

Bio-naive Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics - Results from the National Swedish Rheumatology Quality Register
Turesson C, Stawiarz L, Lindblad S, Saevarsdottir S
ARTHRITIS & RHEUMATOLOGY 2014;:S217-S217

Drug survival in patients receiving golimumab treatment 2010-2013: results from the Swedish Rheumatology Quality register
Saevarsdottir S, Santacatterina M, Stawiarz L, Turesson C, Forsblad-d'elia H, Jacobsson L, et al
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY 2014;:64-64

Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy
Ferreira D, Voevodskaya O, Imrell K, Stawiarz L, Spulber G, Wahlund Lo, et al
Journal of neuroimmunology 2014;274(1-2):149-54

New data identify an increasing sex ratio of multiple sclerosis in Sweden
Westerlind H, Boström I, Stawiarz L, Landtblom Am, Almqvist C, Hillert J
Multiple sclerosis (Houndmills, Basingstoke, England) 2014;20(12):1578-83

Number of OCBs in CSF at diagnosis timepoint,- predictor of long term radiological outcome in MS?
Karrenbauer Vd, Evertsson B, Stawiarz L, Imrell K, Voevodskayac O, Wahlund Lo, et al
JOURNAL OF NEUROIMMUNOLOGY 2014;275(1-2):16-17

Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept Results from the National Swedish Rheumatology Quality Register.
Turesson C, Stawiarz L, Lindblad S, Saevarsdottir S
ARTHRITIS & RHEUMATOLOGY 2014;:S221-S221

The influence of immunomodulatory treatment on the clinical course of multiple sclerosis
Kavaliunas A, Stawiarz L, Glaser A, Hillert J
MULTIPLE SCLEROSIS JOURNAL 2014;:192-192

Callosal atrophy in multiple sclerosis is related to cognitive speed
Bergendal G, Martola J, Stawiarz L, Kristoffersen-wiberg M, Fredrikson S, Almkvist O
MULTIPLE SCLEROSIS JOURNAL 2013;19(7):969-969

Callosal atrophy in multiple sclerosis is related to cognitive speed
Bergendal G, Martola J, Stawiarz L, Kristoffersen-wiberg M, Fredrikson S, Almkvist O
Acta neurologica Scandinavica 2013;127(4):281-9

Drug Survival In Patients Receiving Golimumab Treatment 2010-2013. Results From The Swedish Rheumatology Quality Register
Saevarsdottir S, Santacatterina M, Stawiarz L, Turesson C, Forsblad H, Jacobsson Lth, et al
ARTHRITIS AND RHEUMATISM 2013;:S641-S642

PREVIOUS BIOLOGICAL THERAPIES INFLUENCE DRUG SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTS STARTING ABATACEPT TREATMENT 2006-2012
Saevarsdottir S, Stawiarz L, Turesson C, Linblad S
ANNALS OF THE RHEUMATIC DISEASES 2013;:626-627

Sex ratio of multiple sclerosis in the National Swedish MS Register (SMSreg)
Boström I, Stawiarz L, Landtblom Am
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(1):46-52

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs
Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, et al
Multiple sclerosis (Houndmills, Basingstoke, England) 2013;19(6):765-74

Callosal atrophy in multiple sclerosis is related to cognitive speed
Bergendal G, Martola J, Stawiarz L, Kristoffersen-wiberg M, Fredrikson S, Almkvist O
EUROPEAN JOURNAL OF NEUROLOGY 2012;:353-353

Cross-sectional study on relationship between Symbol Digit Modalities Test, plasma cerebrosterol concentration and MRI-based brain volumes of MS patients
Bergendal G, Stawiarz L, Almkvist O, Fredrikson S, Glaser A, Hillert J, et al
EUROPEAN JOURNAL OF NEUROLOGY 2012;:711-711

GENDER AND PREVIOUS TREATMENT INFLUENCE OUTCOMES FROM ABATACEPT IN A 5-YEAR RHEUMATOID ARTHRITIS COHORT
Swedish Rheumatology Quality, Lindblad S, Stawiarz L
ANNALS OF THE RHEUMATIC DISEASES 2012;:383-383

Plasma cerebrosterol measures predict cognitive processing speed deterioration 7 years later in MS patients
Stawiarz L, Bergendal G, Almkvist O, Fredrikson S, Link J, Leoni V, et al
MULTIPLE SCLEROSIS JOURNAL 2012;:496-497

Clinical Effect of Abatacept in Patients with Rheumatoid Arthritis, Data From the Swedish Rheumatology Quality Registry
Nisell R, Stawiarz L, Lindblad S
ARTHRITIS AND RHEUMATISM 2011;63(10):S478-S479

A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images
Martola J, Bergstrom J, Fredrikson S, Stawiarz L, Hillert J, Zhang Y, et al
NEURORADIOLOGY 2010;52(2):109-17

One-Dimensional-Ratio Measures of Atrophy Progression in Multiple Sclerosis as Evaluated by Longitudinal Magnetic Resonance Imaging
Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, et al
ACTA RADIOLOGICA 2009;50(8):924-32

Current immunotherapy in relapsing-remitting MS reduces the risk of transition to secondary progression. A 10-year study using virtual placebo technique based on hazard functions
Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Anderson O
EUROPEAN JOURNAL OF NEUROLOGY 2008;:26-26

Gender ratio in the National Swedish MS Register
Landthlom Am, Bostrom I, Stawiarz L, Severinson G, Hillert J
MULTIPLE SCLEROSIS 2008;:S72-S72

Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J
MULTIPLE SCLEROSIS 2008;14(5):679-90

Rate of ventricular enlargement in multiple sclerosis: A nine-year magnetic resonance imaging follow-up study
Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, et al
ACTA RADIOLOGICA 2008;49(5):570-9

The waiting room interface - patients' self-registration in the national Swedish MS-registry
Landtblom Am, Ahlin Cg, Rangsjo G, Johansson G, Severinson G, Stawiarz L, et al
EUROPEAN JOURNAL OF NEUROLOGY 2008;:356-357

[Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]
Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Oluf A
Lakartidningen 2007;104(22):1684-8

Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development
Juha M, Leszek S, Sten F, Jan H, Jakob B, Olof F, et al
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 2007;78(4):375-80

The National Swedish MS register detects an unexpectedly high prevalence in Sweden
Swedish Ms Registry, Landtblom Am, Stawiarz L, Ahlgren C, Andersen O, Callander M, et al
MULTIPLE SCLEROSIS 2007;:S104-S104

[The Swedish MS registry points out an important clinical problem: physical and psychological fatigue is a main symptom in multiple sclerosis]
Landtblom Am, Flensner G, Callander M, Stawiarz L
Lakartidningen 2004;101(44):3456-7

Decreased levels of CD95 and caspase-8 mRNA in multiple sclerosis patients with gadolinium-enhancing lesions on MRI
Gomes Ac, Morris M, Stawiarz L, Jonsson G, Putheti P, Bronge L, et al
NEUROSCIENCE LETTERS 2003;352(2):101-4

Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables
Putheti P, Morris M, Stawiarz L, Teleshova N, Kivisakk P, Pashenkov M, et al
EUROPEAN JOURNAL OF NEUROLOGY 2003;10(5):529-35

Regression analysis of metabolite concentrations estimated from localized proton MR spectra of active and chronic multiple sclerosis lesions
Helms G, Stawiarz L, Kivisakk P, Link H
MAGNETIC RESONANCE IN MEDICINE 2000;43(1):102-10

Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis
Jin Yp, De Pedro-cuesta J, Soderstrom M, Stawiarz L, Link H
JOURNAL OF THE NEUROLOGICAL SCIENCES 2000;181(1-2):56-64

Epidemiological assessment of levodopa use in Spain, 1990-1995. Persistent, low consumption in the South
Cuadrado Ji, De Pedro-cuesta J, Abraira V, Stawiarz L, Inesta A, Almazan J
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 1999;8(6):433-45

High numbers of perforin mRNA expressing CSF cells in multiple sclerosis patients with gadolinium-enhancing brain MRI lesions
Kivisakk P, Stawiarz L, Matusevicius D, Fredrikson S, Soderstrom M, Hindmarsh T, et al
ACTA NEUROLOGICA SCANDINAVICA 1999;100(1):18-24

Incidence of optic neuritis in Stockholm, Sweden 1990-1995: I. Age, sex, birth and ethnic-group related patterns
Jin Yp, De Pedro-cuesta J, Soderstrom M, Stawiarz L, Link H
JOURNAL OF THE NEUROLOGICAL SCIENCES 1998;159(1):107-14

HIGH LEVODOPA USE IN PERIODICALLY TIME-CLUSTERED, ICELANDIC BIRTH COHORTS - A VESTIGE OF PARKINSONISM ETIOLOGY
Depedrocuesta J, Petersen Ij, Stawiarz L, Gudmundsson G, Gudmundsson G, Almazan J, et al
ACTA NEUROLOGICA SCANDINAVICA 1995;91(2):79-88

High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? Europarkinson Preparatory Activity Research Group
De Pedro-cuesta J, Petersen Ij, Stawiarz L, Gudmundsson G, Gudmundsson G, Almazán J, et al
Acta neurologica Scandinavica 1995;91(2):79-88

LEVODOPA USE IN DENMARK - HIGH-LEVELS IN GREENLAND AND THE FAROE ISLANDS
Depedrocuesta J, Wermuth L, Abraira V, Stawiarz L
ACTA NEUROLOGICA SCANDINAVICA 1995;91(2):89-97

Levodopa use in Denmark: high levels in Greenland and the Faroe Islands. Europarkinson Preparatory Activity Research Group
De Pedro-cuesta J, Wermuth L, Abraira V, Stawiarz L
Acta neurologica Scandinavica 1995;91(2):89-97

Show all publications